Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes
暂无分享,去创建一个
N. Takahashi | M. Miura | T. Niioka | Kumi Ubukawa | M. Nara | N. Fujishima | M. Fujishima | Maiko Abumiya | T. Yamashita
[1] E. R. van den Heuvel,et al. Voriconazole metabolism is influenced by severe inflammation: a prospective study , 2017, The Journal of antimicrobial chemotherapy.
[2] D. Touw,et al. Comment on: Utility of voriconazole therapeutic drug monitoring: a meta-analysis. , 2016, The Journal of antimicrobial chemotherapy.
[3] S. Zhai,et al. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis , 2016, European Journal of Clinical Pharmacology.
[4] Y. Nannya,et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. , 2016, The Journal of antimicrobial chemotherapy.
[5] W. Haefeli,et al. Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole , 2016, Clinical Pharmacokinetics.
[6] K. Naruhashi,et al. A retrospective analysis of patient-specific factors on voriconazole clearance , 2016, Journal of Pharmaceutical Health Care and Sciences.
[7] E. R. van den Heuvel,et al. Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations , 2016, Antimicrobial Agents and Chemotherapy.
[8] M. Andréjak,et al. High metabolic N‐oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype , 2015, British journal of clinical pharmacology.
[9] Takahiro Yamada,et al. Saturated Metabolism of Voriconazole N-Oxidation Resulting in Nonlinearity of Pharmacokinetics of Voriconazole at Clinical Doses. , 2015, Biological & pharmaceutical bulletin.
[10] Krista L. Niece,et al. In Vitro Study of the Variable Effects of Proton Pump Inhibitors on Voriconazole , 2015, Antimicrobial Agents and Chemotherapy.
[11] H. Elewa,et al. Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review , 2015, Clinical Pharmacokinetics.
[12] Sameer S. Kadri,et al. Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole , 2015, Current Fungal Infection Reports.
[13] Takahiro Yamada,et al. Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[14] H. Yamazaki,et al. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. , 2015, Current drug metabolism.
[15] E. R. van den Heuvel,et al. Inflammation Is Associated with Voriconazole Trough Concentrations , 2014, Antimicrobial Agents and Chemotherapy.
[16] Julie A. Johnson,et al. CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics? , 2014, Pharmacotherapy.
[17] A. McLachlan,et al. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. , 2014, The Journal of antimicrobial chemotherapy.
[18] Y. Nishi,et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[19] A. McLachlan,et al. Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring , 2012, Antimicrobial Agents and Chemotherapy.
[20] Takahiro Yamada,et al. Rapid simultaneous determination of voriconazole and its N-oxide in human plasma using an isocratic high-performance liquid chromatography method and its clinical application. , 2012, Clinical biochemistry.
[21] N. Wood,et al. Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use , 2011, Antimicrobial Agents and Chemotherapy.
[22] Wei-Hua Wu,et al. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism , 2010, European Journal of Clinical Pharmacology.
[23] W. Haefeli,et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. , 2009, British journal of clinical pharmacology.
[24] P. Hoogerbrugge,et al. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. , 2008, Therapeutic drug monitoring.
[25] J. Donnelly,et al. Therapeutic Drug Monitoring of Voriconazole , 2008, Therapeutic drug monitoring.
[26] Edward T. Morgan,et al. Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes , 2007, Drug Metabolism and Disposition.
[27] L. Scott,et al. Voriconazole : a review of its use in the management of invasive fungal infections. , 2007, Drugs.
[28] Leif Bertilsson,et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.
[29] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.
[30] M. Ruhnke,et al. Voriconazole: review of a broad spectrum triazole antifungal agent , 2005, Expert opinion on pharmacotherapy.
[31] M. Sasaki,et al. The Effect of Aging on the Relationship between the Cytochrome P450 2C19 Genotype and Omeprazole Pharmacokinetics , 2005, Clinical pharmacokinetics.
[32] K. Renton. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. , 2004, Current drug metabolism.
[33] D A Smith,et al. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[34] M. Hiratsuka,et al. PHARMACOKINETICS AND DISPOSITION , 2002 .
[35] N. Wood,et al. Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.
[36] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.
[37] S. Higuchi,et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. , 1998, Therapeutic drug monitoring.
[38] E. Morgan. Regulation of cytochromes P450 during inflammation and infection. , 1997, Drug metabolism reviews.
[39] G R Wilkinson,et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.
[40] E. Mini,et al. Pharmacokinetic Drug Interactions of Macrolides , 1992, Clinical pharmacokinetics.
[41] D. Koutras,et al. Thyroidal iodinated compounds in nodular goitre. , 1968, Clinica chimica acta; international journal of clinical chemistry.